| scholarly article | Q13442814 |
| P50 | author | Andrej Šali | Q4756078 |
| Daniel A. Keedy | Q37391464 | ||
| Dina Schneidman-Duhovny | Q47155716 | ||
| James S Fraser | Q47451343 | ||
| Rahel A Woldeyes | Q57308151 | ||
| Patrick Weinkam | Q114333930 | ||
| P2093 | author name string | Peter Cimermancic | |
| James A Wells | |||
| Julie C Mitchell | |||
| Leon Bichmann | |||
| T Justin Rettenmaier | |||
| Omar N Demerdash | |||
| P2860 | cites work | Open Babel: An open chemical toolbox | Q21198766 |
| The Protein Data Bank | Q24515306 | ||
| Structural conservation of druggable hot spots in protein-protein interfaces | Q24614979 | ||
| ASD: a comprehensive database of allosteric proteins and modulators | Q24616070 | ||
| Druggability Assessment of Allosteric Proteins by Dynamics Simulations in the Presence of Probe Molecules | Q24633124 | ||
| Structure-based activity prediction for an enzyme of unknown function | Q24642801 | ||
| Expanding the number of 'druggable' targets: non-enzymes and protein-protein interactions | Q27003966 | ||
| A novel lipid binding site formed by the MAP kinase insert in p38 alpha | Q27649025 | ||
| Turning a protein kinase on or off from a single allosteric site via disulfide trapping | Q27667313 | ||
| Accessing protein conformational ensembles using room-temperature X-ray crystallography | Q27673946 | ||
| K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions | Q27680654 | ||
| Structure of the TRPV1 ion channel determined by electron cryo-microscopy | Q27680759 | ||
| UCSF Chimera--a visualization system for exploratory research and analysis | Q27860666 | ||
| The Protein Data Bank: a computer-based archival file for macromolecular structures | Q27860989 | ||
| How many drug targets are there? | Q28276660 | ||
| Predicting protein ligand binding sites by combining evolutionary sequence conservation and 3D structure | Q28472023 | ||
| Binding leverage as a molecular basis for allosteric regulation | Q28477089 | ||
| Structure-based druggability assessment of the mammalian structural proteome with inclusion of light protein flexibility | Q28541379 | ||
| Reaching for high-hanging fruit in drug discovery at protein-protein interfaces | Q29547258 | ||
| The druggable genome | Q29547361 | ||
| The Protein Data Bank | Q29616068 | ||
| Small-molecule inhibitors of protein-protein interactions: progressing towards the dream | Q29617758 | ||
| Localization of binding sites in protein structures by optimization of a composite scoring function | Q30356758 | ||
| Full protein flexibility is essential for proper hot-spot mapping. | Q30397411 | ||
| Evolutionary information hidden in a single protein structure | Q30414685 | ||
| Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques | Q33403707 | ||
| Drug-like density: a method of quantifying the "bindability" of a protein target based on a very large set of pockets and drug-like ligands from the Protein Data Bank | Q33453085 | ||
| Quantifying biogenic bias in screening libraries | Q33456687 | ||
| Fpocket: an open source platform for ligand pocket detection. | Q33457742 | ||
| Structure-based predictive models for allosteric hot spots | Q33509504 | ||
| Targeting the disordered C terminus of PTP1B with an allosteric inhibitor | Q33774262 | ||
| Molecular dynamics simulations and drug discovery | Q34061019 | ||
| Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer | Q34087341 | ||
| Understanding and predicting druggability. A high-throughput method for detection of drug binding sites | Q34129648 | ||
| FTMAP: extended protein mapping with user-selected probe molecules | Q34270284 | ||
| Equilibrium fluctuations of a single folded protein reveal a multitude of potential cryptic allosteric sites | Q34323850 | ||
| Protein flexibility and rigidity predicted from sequence | Q34440277 | ||
| FTFlex: accounting for binding site flexibility to improve fragment-based identification of druggable hot spots. | Q34615879 | ||
| Druggable protein interaction sites are more predisposed to surface pocket formation than the rest of the protein surface | Q34625325 | ||
| Cys-scanning disulfide crosslinking and bayesian modeling probe the transmembrane signaling mechanism of the histidine kinase, PhoQ. | Q35067131 | ||
| Discovery of multiple hidden allosteric sites by combining Markov state models and experiments | Q35156860 | ||
| Ligand binding: functional site location, similarity and docking | Q35165255 | ||
| One Crystal, Two Temperatures: Cryocooling Penalties Alter Ligand Binding to Transient Protein Sites | Q35648941 | ||
| Is allostery an intrinsic property of all dynamic proteins? | Q35894622 | ||
| Searching for new allosteric sites in enzymes | Q35975051 | ||
| Functional flexibility of human cyclin-dependent kinase-2 and its evolutionary conservation | Q36281964 | ||
| Binding MOAD, a high-quality protein-ligand database. | Q36454178 | ||
| Impact of mutations on the allosteric conformational equilibrium | Q36570126 | ||
| The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins | Q36604792 | ||
| Binding of small-molecule ligands to proteins: "what you see" is not always "what you get". | Q37372747 | ||
| Structure-based computational analysis of protein binding sites for function and druggability prediction | Q37971212 | ||
| The druggable genome: an update | Q40362716 | ||
| Roles of residues in the interface of transient protein-protein complexes before complexation | Q42567086 | ||
| Protein clefts in molecular recognition and function | Q42845107 | ||
| Testing of the portal hypothesis: analysis of a V32G, F57G, K58G mutant of the fatty acid binding protein of the murine adipocyte | Q43876704 | ||
| Backbone resonance assignment of the 298 amino acid catalytic domain of protein tyrosine phosphatase 1B (PTP1B). | Q44258189 | ||
| Allosteric inhibition of protein tyrosine phosphatase 1B. | Q44982496 | ||
| Computational approaches to identifying and characterizing protein binding sites for ligand design | Q45327964 | ||
| Allosteric inhibition of PTP1B activity by selective modification of a non-active site cysteine residue | Q46504012 | ||
| Allosteric inhibition through core disruption | Q47905570 | ||
| Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites. | Q48498889 | ||
| KFC2: a knowledge-based hot spot prediction method based on interface solvation, atomic density, and plasticity features. | Q51550360 | ||
| Effects of conformational dynamics on predicted protein druggability. | Q53591240 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 709-719 | |
| P577 | publication date | 2016-02-04 | |
| P1433 | published in | Journal of Molecular Biology | Q925779 |
| P1476 | title | CryptoSite: Expanding the Druggable Proteome by Characterization and Prediction of Cryptic Binding Sites | |
| P478 | volume | 428 |
| Q90568175 | Advanced Methods for Accessing Protein Shape-Shifting Present New Therapeutic Opportunities |
| Q38651856 | Allosteric Inhibitors, Crystallography, and Comparative Analysis Reveal Network of Coordinated Movement across Human Herpesvirus Proteases |
| Q98178435 | Allosteric Regulation at the Crossroads of New Technologies: Multiscale Modeling, Networks, and Machine Learning |
| Q56395829 | An expanded allosteric network in PTP1B by multitemperature crystallography, fragment screening, and covalent tethering |
| Q92948154 | Computational and Experimental Druggability Assessment of Human DNA Glycosylases |
| Q64100131 | Conformational landscape alternations promote oncogenic activities of Ras-related C3 botulinum toxin substrate 1 as revealed by NMR |
| Q91973784 | Cosolvent Analysis Toolkit (CAT): a robust hotspot identification platform for cosolvent simulations of proteins to expand the druggable proteome |
| Q88815851 | Cryptic binding sites on proteins: definition, detection, and druggability |
| Q92133857 | Cryptic pocket formation underlies allosteric modulator selectivity at muscarinic GPCRs |
| Q92485756 | Druggability assessment of mammalian Per-Arnt-Sim [PAS] domains using computational approaches |
| Q36354076 | Exploring Non-obvious Hydrophobic Binding Pockets on Protein Surfaces: Increasing Affinities in Peptide-Protein Interactions |
| Q90093382 | Exploring the computational methods for protein-ligand binding site prediction |
| Q53834774 | Exploring the structural origins of cryptic sites on proteins. |
| Q113676144 | FPocketWeb: protein pocket hunting in a web browser |
| Q90683085 | Free-energy landscape of molecular interactions between endothelin 1 and human endothelin type B receptor: fly-casting mechanism |
| Q38681868 | Identification of Multiple Druggable Secondary Sites by Fragment Screening against DC-SIGN. |
| Q64892301 | Inhibitors of protein-protein interactions (PPIs): an analysis of scaffold choices and buried surface area. |
| Q90061707 | Investigating Cryptic Binding Sites by Molecular Dynamics Simulations |
| Q52718221 | Optimized allosteric inhibition of engineered protein tyrosine phosphatases with an expanded palette of biarsenical small molecules. |
| Q99579621 | PI3K inhibitors: review and new strategies |
| Q30398517 | Predicting Protein Dynamics and Allostery Using Multi-Protein Atomic Distance Constraints. |
| Q100307293 | Predicting binding sites from unbound versus bound protein structures |
| Q92331942 | Redox Systems Biology: Harnessing the Sentinels of the Cysteine Redoxome |
| Q62648881 | Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers |
| Q91708289 | Sequence-Derived Markers of Drug Targets and Potentially Druggable Human Proteins |
| Q38978952 | Targeted Protein Degradation by Small Molecules |
| Q36372112 | Unveiling a novel transient druggable pocket in BACE-1 through molecular simulations: Conformational analysis and binding mode of multisite inhibitors. |
Search more.